Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: 28-Jan-2022 10:36:49

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Primary Care Networks

Action category: Action

Title: Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at risk pre-term infants

Broadcast content:

Palivizumab, administered as an intramuscular injection, is used to provide protection against respiratory syncytial virus (RSV) in at-risk patients. Palivizumab is currently part of a UK-wide immunisation schedule under guidance issued by the Joint Committee on Vaccination and Immunisation (JCVI), which recommends its use in premature infants with severe conditions affecting the lungs and/or heart, and some children with impaired immune systems.

An updated UK rapid policy statement published in June 2021 extended the eligibility criteria for passive immunisation with palivizumab to a further group of at-risk infants and allowed for up to 7 doses to be administered. This decision was made in the context of the current COVID-19 pandemic and was informed by the unusual seasonal presentation of the virus.

Based on the latest clinical and epidemiological data, provision of palivizumab passive immunisation to the existing and additional cohorts should now be stopped at the end of January 2022.

Alert reference: CEM/CMO/2022/003


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency